Arcutis has completed enrollment in a 101-patient Phase 2, open-label study of once-daily roflumilast cream 0.05% (ZORYVE) in infants 3 months to under 24 months with mild to moderate atopic dermatitis, with topline safety readout expected in Q1 2026. The study runs for four weeks and follows an earlier maximal-usage pharmacokinetics trial in the same age group. The company already holds U.S. approval for the 0.05% strength in children ages 2 to 5, cleared in October 2025.
The core move is a label-extension play into the youngest pediatric segment, where non-steroidal options remain limited and prescribing patterns are shaped early. By locking in the “last patient in” milestone on an infant-focused safety and tolerability trial, Arcutis is advancing the package it needs to argue for efficacy extrapolation from older pediatric cohorts, supported by exposure data. The design—a short, open-label safety study under maximal-use conditions—aligns with the FDA’s receptivity to pediatric extrapolation for topicals when disease course and response are reasonably consistent across ages.
Strategically, this is about defending and expanding a steroid-sparing franchise in atopic dermatitis while competitive dynamics shift. Crisaborole remains the principal non-steroidal benchmark in infants, and corticosteroids are entrenched first-line with payer-backed step edits. Extending roflumilast to 3 months would give prescribers a PDE4 alternative across nearly the full pediatric continuum, simplifying treatment algorithms and potentially strengthening Arcutis’s negotiating position on formularies. It also rationalizes the company’s dual-strength portfolio: 0.05% for younger children and 0.15% for older patients, creating age-tailored dosing without ceding the earliest-life segment to a competitor.
For sites and CROs, infant dermatology studies are operationally feasible but require careful execution. Open-label safety reduces burden relative to blinded efficacy trials, yet maximal-use protocols in infants demand tight oversight of application amounts, body surface area covered, and adherence—factors that can materially affect systemic exposure in this population. Expect emphasis on caregiver training, diary compliance, and infection surveillance, along with assay work to characterize exposure margins under real-world, high-coverage use. Enrollment velocity here suggests parent demand for non-steroidal options and the practicality of a four-week, once-daily regimen—signals relevant to other sponsors contemplating infant cohorts in inflammatory skin disease.
Regulators will look for a clean safety profile, low systemic absorption, and consistency with prior pediatric data. Any signals of gastrointestinal adverse events, application-site reactions, or infection upticks will be scrutinized, as will laboratory parameters where collected. The small N and short duration are typical for topical pediatric safety packages, but they raise the bar on PK quality and completeness of maximal-use exposure modeling if Arcutis intends to rely on extrapolation for efficacy.
The next catalyst is the Q1 2026 topline. If safety and PK align with expectations, Arcutis could move quickly to an sNDA targeting infants 3 months to under 2 years, setting up a competitive inflection with crisaborole and a fresh round of payer negotiations on step therapy and parity. Risks include the limits of an open-label, four-week dataset to satisfy regulators for the youngest age band, potential exposure variability under maximal-use conditions, and the commercial challenge of unlocking access in a category still biased toward inexpensive topical steroids. Watch for details on systemic exposure under high BSA use, infection rates, and any postmarketing commitments proposed alongside a filing—these will determine how rapidly the label can extend and how strongly the product can anchor the infant segment.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
